SIETES :: 92794 citas

Resultados de la búsqueda por NALTREXONA REFINAR BÚSQUEDA

1.

Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]

2.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]

3.

McCarthy M. US needs $1.1bn to treat opioid addiction. BMJ 2016;352:i694. [Ref.ID 100047]

4.

Anónimo. Dangers de l'anorexigène Mysimba: mobilisation citoyenne bienvenue. Prescrire 2015;35:305. [Ref.ID 99129]

5.

Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]

6.

Anónimo. Diet, drugs, and surgery for weight loss. Med Lett Drugs Ther 2015;57:21-8. [Ref.ID 98856]

7.

Anónimo. FDA approves weight-management drug Contrave. U.S. Food and Drug Administration 2014:10 de septiembre. [Ref.ID 97890]

8.

Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass E, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014;311:1889-900. [Ref.ID 97596]

9.

Spence D. Bad medicine: nalmefene in alcohol misuse. BMJ 2014;348:g1531. [Ref.ID 97333]

10.

Anónimo. Nalméfène. Prescrire 2014;34:6-9. [Ref.ID 97005]

11.

Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2013;311:74-86. [Ref.ID 96313]

12.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506-13. [Ref.ID 90683]

13.

Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet 2011;377:1468-70. [Ref.ID 90674]

14.

Karila L, Weinstein A, Aubin H-J, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010;69:578-92. [Ref.ID 88517]

15.

Anónimo. A morphine/naltrexone combination (Embeda) for pain. Med Lett Drugs Ther 2010;52:22-3. [Ref.ID 88306]

16.

Anónimo. Alcoolodépendance: après le sevrage. Troisième partie. Certains médicaments sont utiles comme adjuvants au soutien médical. Prescrire 2009;29:361-8. [Ref.ID 85790]

17.

Schuckit MA. Alcohol-use disorders. Lancet 2009;373:492-501. [Ref.ID 85216]

18.

Plieth J. Obesity: what next after the CB1 antagonists' failure?. Scrip 2008;3411/3412:44-7. [Ref.ID 84469]

19.

Schottenfield RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2192-200. [Ref.ID 83433]

20.

Hall WD, Mattick RP. Oral substitution treatments for opioid dependence. Lancet 2008;371:2150-1. [Ref.ID 83424]